THU0456 EVALUATION OF THE USE OF ORLISTAT IN THE COMPLEX TREATMENT OF OBESITY IN PATIENTS WITH KNEE OSTEOARTHRITIS

Abstract

Background: Currently in the world there is a pandemic of obesity, which leads to an increase in diseases associated with overweight. Obesity is an important factor in the development and progression of osteoarthritis (OA). The metabolic phenotype of OA, which is directly associated with obesity, is highlighted. Due to the growing number of patients with obesity and OA, a high level of comorbidity and the lack of effectiveness of non-drug therapy, the problem of the effectiveness and safety of the therapy of obesity is very relevant. Objectives: To evaluate the efficacy and safety of drug therapy for obesity in patients with OA of the knee. Methods: 50 female patients (45-65 y.o.) with Kellgren-Lawrence stage II-III KOA and obesity (BMI>30kg/m²). Patients in Group 1 (n = 25) took 120 mg of orlistat 3 times a day in combination with a low-calorie diet and exercise for 6 months. Patients in Group 2 (n = 25) were on a low-calorie diet combined with exercise for 6 months. All patients initially received various non-steroidal anti-inflammatory drugs (NSAIDs) in tablet form. All patients were assessed for body mass, parameters of the WOMAC index, EQ-5D quality of life index, NSAID consumption, and orlistat therapy safety assessment. Results: After 6 months of drug therapy for obesity, patients from Group 1 achieved a significant weight loss by 10.07% (p 0.05). Patients from Group 1 improved the WOMAC index: pain decreased by 52.5% (p Conclusion: The results of our study showed a significant decrease in body weight by more than 10% in the group of patients with OA while receiving orlistat. Significant weight loss helps reduce pain intensity, improve joint function, improves the quality of life of patients with OA, reduces the need for NSAIDs, which can help stabilize other comorbid diseases in patients with OA and obesity. The study noted good safety of therapy with orlistat; no serious adverse reactions were reported. Thus, drug therapy for obesity using orlistat can be included in the management of patients with OA and obesity, who cannot achieve weight loss using non-drug methods. Disclosure of Interests: : Ekaterina Strebkova: None declared, Ludmila Alekseeva Speakers bureau: Bayer, Boeringer-ingelheim, Gedeon-Richter, Servier